Submission based on statistically significant event-free and overall survival data from the Phase 3 EV-304 trial Building on the existing indica...
This marks the third milestone achieved under the collaboration and reflects the steady progress of the pipeline Under the terms of the agreement, Nxe...
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its new ...
NBI-1117570 is an investigational oral, dual muscarinic M1/M4 selective receptor agonist discovered by Nxera advancing through clinical development und...
NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based in South Korea, announced that it has entered into an exclusive dis...
Efficient production of Adeno-Associated Virus (AAV) vectors at scale for in vivo gene therapies remains a key bottleneck for broad patient access an...
Meiji Seika Pharma Co., Ltd. announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company deve...
Expands Otsuka portfolio in psychiatric and neurological fields and aims to accelerate development of Transcend's portfolio, including the TSND-201 progr...
Nelipak® Corporation (“Nelipak”), a leading global provider of healthcare packaging solutions, announced the opening of its new Asi...
Beginning a new drug discovery collaboration using Congruence’s globally recognized Revenir™ platform for the creation of small molecule ...
Meiji Seika Pharma Co., Ltd. announced that morcamilast (proposed international nonproprietary name; development code: ME3183), a selective phosphodieste...
Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its co...
Cloud-based AI application for colorectal cancer prevention: Enhancing detection of clinically significant lesions without compromising safety and workfl...
Year-to-Date Revenue Declined by 2.8% at Constant Exchange Rate (CER), 3.3% atActual Exchange Rates (AER); Impact of VYVANSE® Generics is T...
© 2026 Biopharma Boardroom. All Rights Reserved.
